首页> 外文OA文献 >External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale
【2h】

External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale

机译:用于乳腺癌中HER2的分析前和分析免疫组化测定的外部质量评估(EQA)计划:区域规模的经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: An External Quality Assessment (EQA) program was developed to investigate the state of the art of HER2 immunohistochemical determination in breast cancer (BC) in 16 Pathology Departments in the Lazio Region (Italy). This program was implemented through two specific steps to evaluate HER2 staining (step 1) and interpretation (step 2) reproducibility among participants. Methods. The management activities of this EQA program were assigned to the Coordinating Center (CC), the Revising Centers (RCs) and the Participating Centers (PCs). In step 1, 4 BC sections, selected by RCs, were stained by each PC using their own procedures. In step 2, each PC interpreted HER2 score in 10 BC sections stained by the CC. The concordance pattern was evaluated by using the kappa category-specific statistic and/or the weighted kappa statistic with the corresponding 95% Jackknife confidence interval. Results: In step 1, a substantial/almost perfect agreement was reached between the PCs for scores 0 and 3+ whereas a moderate and fair agreement was observed for scores 1+ and 2+, respectively.In step 2, a fully satisfactory agreement was observed for 6 out of the 16 PCs and a quite satisfactory agreement was obtained for the remaining 10 PCs. Conclusions: Our findings highlight that in the whole HER2 evaluation process the two intermediate categories, scores 1+ and 2+, are less reproducible than scores 0 and 3+. These findings are relevant in clinical practice where the choice of treatment is based on HER2 positivity, suggesting the need to share evaluation procedures within laboratories and implement educational programs
机译:背景:开发了外部质量评估(EQA)程序,以调查意大利拉齐奥地区16个病理科的HER2免疫组化测定乳腺癌(BC)的技术水平。该程序通过两个特定步骤实施,以评估参与者之间的HER2染色(步骤1)和解释(步骤2)的可重复性。方法。此EQA计划的管理活动已分配给协调中心(CC),修订中心(RC)和参与中心(PC)。在第1步中,每个PC使用自己的程序对由RC选择的4个BC切片进行染色。在第2步中,每台PC解释CC染色的10个BC切片中的HER2得分。通过使用特定于kappa类别的统计信息和/或具有相应95%Jackknife置信区间的加权kappa统计信息来评估一致性模式。结果:在步骤1中,PC之间的得分为0和3+,达到了基本/几乎完美的协议,而对于得分1+和2+,则达到了中度和公平的协议。在步骤2中,完全满意的协议是在16台PC中,有6台被观察到,其余10台PC获得了相当令人满意的协议。结论:我们的发现突出表明,在整个HER2评估过程中,得分1+和2+的两个中间类别的可再现性低于得分0和3+。这些发现与临床实践有关,在临床实践中,治疗的选择基于HER2阳性,表明需要在实验室内共享评估程序并实施教育计划

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号